Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease–novel insights into cellular communication circuits

M Peiseler, R Schwabe, J Hampe, P Kubes… - Journal of …, 2022 - Elsevier
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease

G Feng, L Valenti, VWS Wong, YM Fouad… - Nature Reviews …, 2024 - nature.com
Recompensation has gained increasing attention in the field of cirrhosis, particularly in
chronic liver disease with a definite aetiology. The current global prevalence of obesity and …

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

X Xu, KL Poulsen, L Wu, S Liu, T Miyata… - Signal transduction and …, 2022 - nature.com
Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

F Tacke, T Puengel, R Loomba, SL Friedman - Journal of Hepatology, 2023 - Elsevier
Successful development of treatments for non-alcoholic fatty liver disease and its
progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because …

Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities

Y Wen, J Lambrecht, C Ju, F Tacke - Cellular & molecular immunology, 2021 - nature.com
Macrophages, which are key cellular components of the liver, have emerged as essential
players in the maintenance of hepatic homeostasis and in injury and repair processes in …

The glycosylation in SARS-CoV-2 and its receptor ACE2

Y Gong, S Qin, L Dai, Z Tian - Signal Transduction and Targeted …, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), a highly infectious disease caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than …

Liver fibrosis: mechanistic concepts and therapeutic perspectives

N Roehlen, E Crouchet, TF Baumert - Cells, 2020 - mdpi.com
Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global
health. Correlating with liver disease progression, fibrosis is a key factor for liver disease …

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

CK Negi, P Babica, L Bajard, J Bienertova-Vasku… - Metabolism, 2022 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Therapeutic pipeline in nonalcoholic steatohepatitis

R Vuppalanchi, M Noureddin, N Alkhouri… - Nature reviews …, 2021 - nature.com
Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …

Targeting galectin-driven regulatory circuits in cancer and fibrosis

KV Mariño, AJ Cagnoni, DO Croci… - Nature Reviews Drug …, 2023 - nature.com
Galectins are a family of endogenous glycan-binding proteins that have crucial roles in a
broad range of physiological and pathological processes. As a group, these proteins use …